Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA

Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418

Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis

Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O’Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792

Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive

Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., & Welsh, M. J. (1992) · Nature · doi:10.1038/358761a0 · Cited by 1,236

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Goor, F. V., Hadidaꝉ, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A. K., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,225

Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report

Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., LeGrys, V. A., Massie, J., Parad, R. B., et al. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.005 · Cited by 1,093

Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screening

Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation

Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M., Dunitz, J., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 803

Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation

Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Jallat, S., Dott, K., Dreyer, D., Crystal, R. G., Pavirani, A., Lecocq, J.-P., et al. (1991) · Nature · doi:10.1038/354526a0 · Cited by 707

Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice

Castellani, C., Cuppens, H., Maçek, M., Cassiman, J. J., Kerem, E., Durie, P. R., Tullis, E. D., Assael, B. M., Bombieri, C., Brown, A., et al. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.009 · Cited by 624

Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screening

Pedemonte, N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24898 · Cited by 551

Decreasing Poly(ADP-Ribose) Polymerase Activity Restores ΔF508 CFTR Trafficking

Anjos, S. M., Robert, R., Waller, D., Zhang, D. L., Balghi, H., Sampson, H. M., Ciciriello, F., Lesimple, P., Carlile, G. W., Goepp, J., et al. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00165 · Cited by 16

Targeted Proteomic Quantitation of the Absolute Expression and Turnover of Cystic Fibrosis Transmembrane Conductance Regulator in the Apical Plasma Membrane

McShane, A. J., Bajrami, B., Ramos, A. A., Diego, P. A., Farrokhi, V., Coutermarsh, B., Stanton, B. A., Jensen, T., Riordan, J. R., Wetmore, D. R., et al. (2014) · Journal of Proteome Research · doi:10.1021/pr5006795 · Cited by 16

The novel p.Ser263Phe mutation in the human high‐affinity choline transporter 1 (CHT1/ SLC5A7 ) causes a lethal form of fetal akinesia syndrome

Banerjee, M., Arutyunov, D., Brandwein, D., Janetzki‐Flatt, C., Kolski, H., Hume, S. L., Leonard, N., Watt, J., Lacson, A. G., Baradi, M., et al. (2019) · Human Mutation · doi:10.1002/humu.23828 · Cited by 16

Identification, Structure–Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indoles as a Novel Class of CFTR Potentiators

Brindani, N., Gianotti, A., Giovani, S., Giacomina, F., Fruscia, P. D., Sorana, F., Bertozzi, S. M., Ottonello, G., Goldoni, L., Penna, I., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01050 · Cited by 16

Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E–CFTR mutation

Berkers, G., van der Meer, R., Heijerman, H. G. M., Beekman, J. M., Boj, S. F., Vries, R. G. J., van Mourik, P., Doyle, J. R., Audhya, P., Yuan, Z. (., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.11.007 · Cited by 17

Organoid Technology and Its Role for Theratyping Applications in Cystic Fibrosis

Conti, J., Sorio, C., & Melotti, P. (2022) · Children · doi:10.3390/children10010004 · Cited by 18

Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator and Drugs: Insights from Cellular Trafficking

Bridges, R. J., & Bradbury, N. A. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_103 · Cited by 16

Rescue of CFTR NBD2 mutants N1303K and S1235R is influenced by the functioning of the autophagosome

Liu, Q., Sabirzhanova, I. B., Yanda, M. K., Bergbower, E. A. S., Boinot, C., Guggino, W. B., & Cebotaru, L. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.05.016 · Cited by 16

Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis

Yeh, J., Yu, Y., & Hwang, T. (2018) · The Journal of Physiology · doi:10.1113/jp277042 · Cited by 16

Targeting different binding sites in the CFTR structures allows to synergistically potentiate channel activity

Froux, L., Elbahnsi, A., Boucherle, B., Billet, A., Baatallah, N., Hoffmann, B., Alliot, J., Zelli, R., Zeinyeh, W., Haudecoeur, R., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112116 · Cited by 16

An unfolding story: Small molecules remedy misfolded monoamine transporters

Kasture, A. S., Stockner, T., Freissmuth, M., & Sučić, S. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.09.004 · Cited by 16

Mechanism of dual pharmacological correction and potentiation of human CFTRPreprint

Wang, C., Yang, Z. W., Loughlin, B. J., Xu, H., Veit, G., Vorobiev, S. M., Clarke, O. B., Jiang, F., Li, Y., Singh, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.10.510913 · Cited by 17

Effects of environmental air pollutants on CFTR expression and function in human airway epithelial cells

Nguyen, J., Huff, R. D., Cao, Q., Tiessen, N., Carlsten, C., & Hirota, J. A. (2021) · Toxicology in Vitro · doi:10.1016/j.tiv.2021.105253 · Cited by 15

Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis

Wang, X., Tse, C., & Singh, A. K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02547 · Cited by 15

Simple image-based no-wash method for quantitative detection of surface expressed CFTR

Larsen, M. B., Hu, J., Frizzell, R. A., & Watkins, S. C. (2015) · Methods · doi:10.1016/j.ymeth.2015.09.006 · Cited by 15

Therapeutic Targeting of Misfolding and Conformational Change in α 1 -Antitrypsin Deficiency

Nyon, M. P., & Gooptu, B. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.58 · Cited by 15

Potentiation of the cystic fibrosis transmembrane conductance regulator Cl−channel by ivacaftor is temperature independent

Wang, Y., Cai, Z., Gosling, M., & Sheppard, D. N. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00235.2018 · Cited by 15

The ΔF508-CFTR mutation inhibits wild-type CFTR processing and function when co-expressed in human airway epithelia and in mouse nasal mucosa

Tucker, T. A., Fortenberry, J. A., Zsembery, Á., Schwiebert, L. M., & Schwiebert, E. M. (2012) · BMC Physiology · doi:10.1186/1472-6793-12-12 · Cited by 15

Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR chloride channel

Pesce, E., Gorrieri, G., Sirci, F., Napolitano, F., Carrella, D., Caci, E., Tomati, V., Zegarra‐Moran, O., di Bernardo, D., & Galietta, L. J. V. (2016) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2016.02.009 · Cited by 15

A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria

Bustad, H. J., Toska, K., Schmitt, C., Vorland, M., Skjærven, L., Kallio, J. P., Simonin, S., Lettéron, P., Underhaug, J., Sandberg, S., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.010 · Cited by 15

VX‐809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation

Yanda, M. K., & Cebotaru, L. (2021) · The FASEB Journal · doi:10.1096/fj.202101315r · Cited by 14

Cystic Fibrosis: therapies targeting specific gene defects

Thursfield, R., & Davies, J. C. (2012) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2012.04.003 · Cited by 14

Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis

Muilwijk, D., Ommen, D. D. Z.-V., Gulmans, V. A. M., Eijkemans, M. J. C., van der Ent, C. K., Dutch Cystic Fibrosis Registry (NCFR) Steering Group:, Altenburg, J., Terheggen‐Lagro, S. W. J., Heijerman, H. G. M., Groot, K. M. D. W., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00204-2022 · Cited by 14

Redefining Hypo- and Hyper-Responding Phenotypes of CFTR Mutants for Understanding and Therapy

Hillenaar, T., Beekman, J. M., van der Sluijs, P., & Braakman, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315170 · Cited by 14

Function, pharmacological correction and maturation of new Indian CFTR gene mutations

Sharma, H., Souchet, M. J., Callebaut, I., Prasad, R., & Becq, F. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.06.008 · Cited by 14

Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation

Dilokthornsakul, P., Patidar, M., & Campbell, J. D. (2017) · Value in Health · doi:10.1016/j.jval.2017.06.014 · Cited by 14

Gene editing & stem cells

Harrison, P. T., Hoppe, N., & Martin, U. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.11.018 · Cited by 14

Novel Human Polymorphisms Define a Key Role for the SLC26A6-STAS Domain in Protection From Ca2+-Oxalate Lithogenesis

Shimshilashvili, L., Aharon, S., Moe, O. W., & Ohana, E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00405 · Cited by 14

Molecular dynamics and functional characterization of I37R-CFTR lasso mutation provide insights into channel gating activity

Wong, S. L., Awatade, N. T., Astore, M. A., Allan, K. M., Carnell, M. J., Šlapetová, I., Chen, P., Capraro, A., Fawcett, L. K., Whan, R. M., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103710 · Cited by 14

Membrane proteins enter the fold

Marx, D. C., & Fleming, K. G. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.03.006 · Cited by 13

Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators

Chatterjee, P., Moss, C. T., Omar, S., Dhillon, E., Borges, C. H., Tang, A. C., Stevens, D. A., & Hsu, J. L. (2024) · Journal of Fungi · doi:10.3390/jof10090656 · Cited by 13

Insulin-Like Growth Factor 1 (IGF-1) Enhances the Protein Expression of CFTR

Lee, H. W., Cheng, J., Kovbasnjuk, O. N., Donowitz, M., & Guggino, W. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059992 · Cited by 13

CFTR Protein Repair Therapy in Cystic Fibrosis

Quintana‐Gallego, E., Delgado‐Pecellín, I., & Acuña, C. C. (2014) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2014.03.002 · Cited by 13

Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis

Bali, V., Lazrak, A., Guroji, P., Matalon, S., & Bebok, Z. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155882 · Cited by 13

Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors

Righetti, G., Casale, M., Liessi, N., Tasso, B., Salis, A., Tonelli, M., Millo, E., Pedemonte, N., Fossa, P., & Cichero, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218084 · Cited by 13

Improved correction of F508del-CFTR biogenesis with a folding facilitator and an inhibitor of protein ubiquitination

Goeckeler-Fried, J. L., Denny, R. A., Joshi, D., Hill, C., Larsen, M. B., Chiang, A., Frizzell, R. A., Wipf, P., Sorscher, E. J., & Brodsky, J. L. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128243 · Cited by 13

Modulator Therapy in Cystic Fibrosis Patients with cis Variants in F508del Complex Allele: A Short-Term Observational Case Series

Terlizzi, V., Centrone, C., Ferrari, B., Castellani, C., Gunawardena, T. N. A., Taccetti, G., & Laselva, O. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091421 · Cited by 13

Degradation mechanism of a Golgi-retained distal renal tubular acidosis mutant of the kidney anion exchanger 1 in renal cells

Chu, C., King, J., Berrini, M., Rumley, A. C., Apaja, P. M., Lukács, G. L., Alexander, R. T., & Cordat, E. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00310.2013 · Cited by 13

Tratamientos reparadores de la proteína CFTR en la fibrosis quística

Quintana‐Gallego, E., Delgado‐Pecellín, I., & Acuña, C. C. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.07.013 · Cited by 13

A Physiologically-Motivated Compartment-Based Model of the Effect of Inhaled Hypertonic Saline on Mucociliary Clearance and Liquid Transport in Cystic Fibrosis

Markovetz, M. R., Corcoran, T. E., Locke, L. W., Myerburg, M. M., Pilewski, J. M., & Parker, R. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111972 · Cited by 13

Structure–activity analysis of a CFTR channel potentiator: Distinct molecular parts underlie dual gating effects

Csanády, L., & Törőcsik, B. (2014) · The Journal of General Physiology · doi:10.1085/jgp.201411246 · Cited by 13

Ivacaftor for the treatment of cystic fibrosis in children under six years of age

Aoyama, B. C., & Mogayzel, P. J. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1741352 · Cited by 12

Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays

Parodi, A. C. L., Righetti, G., Pesce, E., Salis, A., Tasso, B., Urbinati, C., Tomati, V., Damonte, G., Rusnati, M., Pedemonte, N., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112833 · Cited by 13

Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings

Bratcher, P. E., Yadav, S., Shaughnessy, C. A., Thornell, I. M., & Zeitlin, P. L. (2020) · Physiological Reports · doi:10.14814/phy2.14603 · Cited by 13

Image-based screen capturing misfolding status of Niemann-Pick type C1 identifies potential candidates for chaperone drugs

Shioi, R., Karaki, F., YOSHIOKA, H., Noguchi‐Yachide, T., Ishikawa, M., Dodo, K., Hashimoto, Y., Sodeoka, M., & Ohgane, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243746 · Cited by 13

Phenylhydrazones as Correctors of a Mutant Cystic Fibrosis Transmembrane Conductance Regulator

Nieddu, E., Pollarolo, B., Mazzei, M. T., Anzaldi, M., Schenone, S., Pedemonte, N., Galietta, L. J. V., & Mazzei, M. (2015) · Archiv der Pharmazie · doi:10.1002/ardp.201500352 · Cited by 13

Long-term management of patients with end-stage lung diseases

Briganti, D. F., & D’Ovidio, F. (2017) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2017.07.007 · Cited by 18

Virtual Screening of Potential Inhibitors for SARS-CoV-2 Main ProteasePreprint

Alméciga-Díaz, C. J., Pimentel-Vera, L. N., Caro, A., Mosquera, Á., Moreno, C. N. A., Rojas, J. P. M., & Díaz-Tribaldos, D. C. (2020) · Preprints.org · doi:10.20944/preprints202004.0146.v1 · Cited by 13

In Vitro Modulator Responsiveness of 655 CFTR Variants Found in People With CFPreprint

Bihler, H. J., Sivachenko, A., Millen, L., Bhatt, P., Thakerar, A., Chin, J., Bailey, V., Musisi, I., LaPan, A., Allaire, N., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.07.548159 · Cited by 13

Combination of Selective PARP3 and PARP16 Inhibitory Analogues of Latonduine A Corrects F508del-CFTR Trafficking

Centko, R. M., Carlile, G. W., Barne, I., Patrick, B. O., Blagojević, P. D., Thomas, D. Y., & Andersen, R. J. (2020) · ACS Omega · doi:10.1021/acsomega.0c02467 · Cited by 12

Small molecule modulation of protein polymerization

Fischer, E. S., & Jones, L. H. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00070a · Cited by 16

Small-molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding states

Riepe, C., Wąchalska, M., Deol, K. K., Amaya, A. K., Porteus, M. H., Olzmann, J. A., & Kopito, R. R. (2023) · Molecular Biology of the Cell · doi:10.1091/mbc.e23-08-0336 · Cited by 12

Understanding CFTR Functionality: A Comprehensive Review of Tests and Modulator Therapy in Cystic Fibrosis

Thakur, S., Ankita, A., Dash, S., Verma, R., Kaur, C., Kumar, R., Mazumder, A., & Singh, G. (2023) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-023-01200-w · Cited by 12

A uniquely efficacious type of CFTR corrector with complementary mode of action

Marchesin, V., Monnier, L., Blattmann, P., Chevillard, F., Kuntz, C., Forny, C., Kamper, J., Studer, R. O., Bossu, A., Ertel, E. A., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk1814 · Cited by 12

HERC3 facilitates ERAD of select membrane proteins by recognizing membrane-spanning domains

Kamada, Y., Ohnishi, Y., Nakashima, C., Fujii, A., Terakawa, M., Hamano, I., Nakayamada, U., Katoh, S., Hirata, N., Tateishi, H., et al. (2024) · The Journal of Cell Biology · doi:10.1083/jcb.202308003 · Cited by 14

Thermal unfolding simulations of NBD1 domain variants reveal structural motifs associated with the impaired folding of F508del-CFTR

Estácio, S. G., Martiniano, H., & Faísca, P. F. N. (2016) · Molecular BioSystems · doi:10.1039/c6mb00193a · Cited by 11

Quantitative phase imaging to study transmembrane water fluxes regulated by CFTR and AQP3 in living human airway epithelial CFBE cells and CHO cells

Llinares, J., Cantereau, A., Froux, L., & Becq, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233439 · Cited by 12

New Therapeutic Approaches in Cystic Fibrosis

Fakıoğlu, D. M., & Altun, B. (2020) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2020.76401 · Cited by 12

New insights into structure and function of bis-phosphinic acid derivatives and implications for CFTR modulation

Bitam, S., Elbahnsi, A., Creste, G., Pranke, I. M., Chevalier, B., Berhal, F., Hoffmann, B., Servel, N., Baatalah, N., Tondelier, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83240-x · Cited by 12

DNA-modularized construction of bivalent ligands precisely regulates receptor binding and activation

Zhao, N., Wu, W., Wang, Y., Song, K., Chen, G., Chen, Y., Wang, R., Xu, J., Cui, K., Chen, H., et al. (2023) · Chem · doi:10.1016/j.chempr.2022.12.002 · Cited by 12

A Genomic Signature Approach to Rescue ΔF508-Cystic Fibrosis Transmembrane Conductance Regulator Biosynthesis and Function

Ramachandran, S. S., Osterhaus, S. R., Karp, P. H., Welsh, M. J., & McCray, P. B. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0007oc · Cited by 12

Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386 and WO2013038390

Norman, P. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.876412 · Cited by 12

Gaining the Upper Hand on Pulmonary Drug Delivery

Tyrrell, R. T. J. (2014) · Journal of Pharmacovigilance · doi:10.4172/2329-6887.1000118 · Cited by 11

Synthesis of furo[3,4-c]quinolin-3(1H)-one derivatives through TMG catalyzed intramolecular aza-MBH reaction based on the furanones

Yin, D., Wang, W., Peng, Y., Ge, Z., Cheng, T., Wang, X., & Li, R. (2014) · RSC Advances · doi:10.1039/c4ra13796e · Cited by 12

Structure of wild type and mutant F508del CFTR: A small-angle X-ray scattering study of the protein–detergent complexes

Pollock, N. L., Satriano, L., Zegarra‐Moran, O., Ford, R. C., & Morán, Ó. (2016) · Journal of Structural Biology · doi:10.1016/j.jsb.2016.02.004 · Cited by 12

Ligand binding to a remote site thermodynamically corrects the F508del mutation in the human cystic fibrosis transmembrane conductance regulator

Wang, C. C., Aleksandrov, A. A., Yang, Z. W., Forouhar, F., Proctor, E. A., Kota, P. B., An, J., Kaplan, A., Khazanov, N., Boël, G., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000819 · Cited by 12

Sphingomyelinase decreases transepithelial anion secretion in airway epithelial cells in part by inhibiting CFTR‐mediated apical conductance

Cottrill, K. A., Peterson, R. J., Lewallen, C. F., Koval, M. H., Bridges, R. J., & McCarty, N. A. (2021) · Physiological Reports · doi:10.14814/phy2.14928 · Cited by 12

Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII

Wei, W., Zheng, C., Zhu, M., Zhu, X., Yang, R., Misra, S., & Zhang, B. (2017) · Scientific Reports · doi:10.1038/srep45033 · Cited by 12

Germline genetic variants with implications for disease risk and therapeutic outcomes

Pasternak, A. L., Ward, K. M., Luzum, J. A., Ellingrod, V. L., & Hertz, D. L. (2017) · Physiological Genomics · doi:10.1152/physiolgenomics.00035.2017 · Cited by 12

Laboratory Tools to Predict CFTR Modulator Therapy Effectiveness and to Monitor Disease Severity in Cystic Fibrosis

Bacalhau, M., Camargo, M., & Lopes‐Pacheco, M. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010093 · Cited by 11

A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator

Bali, V., Lazrak, A., Guroji, P., Fu, L., Matalon, S., & Bebok, Z. M. (2015) · The FASEB Journal · doi:10.1096/fj.15-273714 · Cited by 12

Three-Dimensional Airway Spheroids and Organoids for Cystic Fibrosis Research

Laselva, O., & Conese, M. (2021) · Journal of Respiration · doi:10.3390/jor1040022 · Cited by 12

Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis

McElvaney, O. J., Heltshe, S. L., Odem‐Davis, K., West, N. E., Sanders, D. B., Fogarty, B., VanDevanter, D. R., Flume, P. A., & Goss, C. H. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.06.012 · Cited by 11

Towards personalized agriculture: what chemical genomics can bring to plant biotechnology

Stokes, M. E., & McCourt, P. (2014) · Frontiers in Plant Science · doi:10.3389/fpls.2014.00344 · Cited by 12

Acute inhibition of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl− channel by thyroid hormones involves multiple mechanisms

Cai, Z., Li, H., Chen, J.-H., & Sheppard, D. N. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00052.2013 · Cited by 11

Cystic Fibrosis

Molina, S. A., & Hunt, W. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803809-3.00012-9 · Cited by 13

Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.

Hanrahan, J. W., Sato, Y., Carlile, G. W., Jansen, G., Young, J. C., & Thomas, D. Y. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1628948 · Cited by 10

Short-term consequences of F508del-CFTR thermal instability on CFTR-dependent transepithelial currents in human airway epithelial cells

Froux, L., Coraux, C., Sage, É., & Becq, F. (2019) · Scientific Reports · doi:10.1038/s41598-019-50066-7 · Cited by 11

Validation of nasospheroids to assay CFTR functionality and modulator responses in cystic fibrosis

Calucho, M., Gärtner, S., Barranco, P., Fernández‐Álvarez, P., Pérez, R. G., & Tizzano, E. F. (2021) · Scientific Reports · doi:10.1038/s41598-021-94798-x · Cited by 12

Efficacy of CFTR modulators in clinical practice (6-month follow-up)

Kondratyeva, E., Odinaeva, N. D., Zhekaite, E. K., Pasnova, E. V., Fatkhullina, I. R., Maksimycheva, T., Sherman, V. D., & Kutsev, S. I. (2023) · PULMONOLOGIYA · doi:10.18093/0869-0189-2023-33-2-189-197 · Cited by 10

Restoring CFTR function with Orkambi decreases the severity of alcohol‐induced acute pancreatitis

Venglovecz, V., Grassalkovich, A., Tóth, E., Èbert, A., Gál, E., Korsós, M. M., Maléth, J., Rakonczay, Z., Galla, Z., Monostori, P. B., et al. (2024) · The Journal of Physiology · doi:10.1113/jp287289 · Cited by 10

Novel Corrector for Variants of SLC6A8: A Therapeutic Opportunity for Creatine Transporter Deficiency

Gechijian, L., Muncipinto, G., Rettenmaier, T. J., Labenski, M., Rusu, V., Rosskamp, L., Conway, L., van Kalken, D., Gross, L., Iantosca, G., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00571 · Cited by 10

F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review

Yang, H. Y., & Ma, T. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1045878 · Cited by 10

Therapeutic Potential for CFTR Correctors in Autosomal Recessive Polycystic Kidney Disease

Yanda, M. K., Tomar, V., & Cebotaru, L. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.07.012 · Cited by 10

The NSAID glafenine rescues class 2 CFTR mutants via cyclooxygenase 2 inhibition of the arachidonic acid pathway

Carlile, G. W., Yang, Q., Matthes, E., Liao, J., Birault, V., Sneddon, H. F., Poole, D. L., Hall, C. J., Hanrahan, J. W., & Thomas, D. Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-08661-8 · Cited by 10

A Proteome-Centric View of Ageing, including that of the Skin and Age-Related Diseases: Considerations of a Common Cause and Common Preventative and Curative Interventions

Benoit, I., Burty-Valin, E., & Radman, M. (2023) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s397751 · Cited by 11

Homo cerevisiae—Leveraging Yeast for Investigating Protein–Protein Interactions and Their Role in Human Disease

Laval, F., Coppin, G., Twizere, J., & Vidal, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119179 · Cited by 10

Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies

Carbone, A., Vitullo, P., Gioia, S. D., & Conese, M. (2023) · Genes · doi:10.3390/genes14101966 · Cited by 10

Potentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel Hydroxypyrazolines

Park, J., Khloya, P., Seo, Y., Kumar, S., Lee, H. K., Jeon, D.-K., Jo, S., Sharma, P. K., & Namkung, W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149131 · Cited by 10

Therapie der Mukoviszidose mit CFTR-Modulatoren

Tümmler, B. (2016) · Pneumologie · doi:10.1055/s-0042-100607 · Cited by 10

Protein and lipid interactions – Modulating CFTR trafficking and rescue

Farinha, C. M., Miller, E. A., & McCarty, N. A. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.08.014 · Cited by 10

Pendrin stimulates a chloride absorption pathway to increase CFTR‐mediated chloride secretion from Cystic Fibrosis airway epithelia

Bajko, J., Duguid, M., Altmann, S., Hurlbut, G. D., & Kaczmarek, J. S. (2020) · FASEB BioAdvances · doi:10.1096/fba.2020-00012 · Cited by 10

New Insights into the Binding Features of F508del CFTR Potentiators: A Molecular Docking, Pharmacophore Mapping and QSAR Analysis Approach

Righetti, G., Casale, M., Tonelli, M., Liessi, N., Fossa, P., Pedemonte, N., Millo, E., & Cichero, E. (2020) · Pharmaceuticals · doi:10.3390/ph13120445 · Cited by 10

Modulation of cAMP metabolism for CFTR potentiation in human airway epithelial cells

Nguyen, J., Bianca, M., Huff, R. D., Tiessen, N., Inman, M. D., & Hirota, J. A. (2021) · Scientific Reports · doi:10.1038/s41598-020-79555-w · Cited by 10

CFTR Lifecycle Map—A Systems Medicine Model of CFTR Maturation to Predict Possible Active Compound Combinations

Vinhoven, L., Stanke, F., Hafkemeyer, S., & Nietert, M. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147590 · Cited by 10

Towards Innovative Antibacterial Correctors for Cystic Fibrosis Targeting the Lung Microbiome with a Multifunctional Effect

Martina, M. G., Sannio, F., Crespan, E., Pavone, M., Simoncini, A., Barbieri, F., Perini, C., Pesce, E., Maga, G., Pedemonte, N., et al. (2022) · ChemMedChem · doi:10.1002/cmdc.202200277 · Cited by 10

CFTR Modulators: From Mechanism to Targeted Therapeutics

Yeh, H., Sutcliffe, K. J., Sheppard, D. N., & Hwang, T. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_597 · Cited by 10

Rescue of Rare CFTR Trafficking Mutants Highlights a Structural Location-Dependent Pattern for Correction

Zacarias, S., Batista, M. S. P., Ramalho, S. S., Victor, B. L., & Farinha, C. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043211 · Cited by 10

A Young Hispanic with c.1646G>A Mutation Exhibits Severe Cystic Fibrosis Lung Disease: Is Ivacaftor an Option for Therapy?

Yarlagadda, S., Zhang, W., Penmatsa, H., Ren, A., Arora, K., Naren, A. P., Khan, F. A. I., Donnellan, C. A., Srinivasan, S., Stokes, D. C., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.186.7.694 · Cited by 10

Endoplasmic Reticulum-Targeted Subunit Toxins Provide a New Approach to Rescue Misfolded Mutant Proteins and Revert Cell Models of Genetic Diseases

Adnan, H., Zhang, Z., Park, H.-J., Tailor, C. S., Che, C., Kamani, M., Spitalny, G. L., Binnington, B., & Lingwood, C. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166948 · Cited by 10

Increased efficacy of VX ‐809 in different cellular systems results from an early stabilization effect of F508del‐ CFTR

Farinha, C. M., Sousa, M., Canato, S., Schmidt, A., Uliyakina, I., & Amaral, M. D. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.152 · Cited by 43

Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function

Arora, K., & Naren, A. P. (2016) · Current Drug Targets · doi:10.2174/1389450117666151209114343 · Cited by 11

Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors

Amico, G., Brandas, C., Morán, Ó., & Baroni, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215463 · Cited by 27

Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment

Capurro, V., Tomati, V., Sondo, E., Renda, M., Borrelli, A., Pastorino, C., Guidone, D., Venturini, A., Giraudo, A., Bertozzi, S. M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105262 · Cited by 72

Revertants, Low Temperature, and Correctors Reveal the Mechanism of F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction

Farinha, C. M., King-Underwood, J., Sousa, M., Correia, A. R., Henriques, B. J., Roxo‐Rosa, M., Paula, A. C. D., Williams, J. P., Hirst, S., Gomes, C. M., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.06.004 · Cited by 164